Panbela Therapeutics Long Term Debt

Panbela Therapeutics (PBLA) currently reports a long-term debt of $0 as of September 2024. That compares with $4.2M in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Panbela Therapeutics's long-term debt history and peer comparisons.

Panbela Therapeutics's long-term debt decreased from $4.2M to $0 — a 100.0% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Panbela Therapeutics reported $0 in long-term debt as of September 2024. That compares with $4.2M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Panbela Therapeutics, and consider following PBLA for alerts when major investors trade the stock.

Panbela Therapeutics is classified in the Technology sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Technology are usually more informative than comparing PBLA with unrelated industries.